Laminar Pharma

LAMINAR PHARMA is a pioneering biopharmaceutical company that focuses on the discovery, rational design and initial clinical development of a new generation of medicines associated with a novel therapeutic approach: Membrane Lipid Therapy (MLT).


LAMINAR PHARMA arose in 2006 with the objective to develop breakthrough inventions patented by the University of the Balearic Islands (UIB) in Mallorca, Spain.

Membrane Lipid Theraphy (MLT)

Membrane Lipid Therapy (MLT) is an innovative and unique technology platform that is based on very specialized scientific knowledge, which allows us to confidently embark on the rational design of new molecules that regulate the structure and function of cell membrane lipids, and their associated proteins.


Recent advances in our understanding of lipid membrane structures and their interactions with peripheral signal transduction proteins have opened the way to develop synthetic lipids that target cell membranes. This approach has led to the development of novel and alternative therapeutic strategies for a number of important pathologies such as Cancer, Neurodegenerative diseases, Metabolic disorders or Inflammation.



Prof. Pablo V. Escriba, PhD.

President & Founder

Adrian G. McNicholl, PhD.


Victoria Llado, PhD.


Daniel Bermejo, MSc.

Clinical Trial manager

Catalina Ana Rossello, PhD.

Clinical R&D projects

Paula Fernandez, PhD.

Director Oncology R&D

Manuel Torres, PhD.

Director Neurology R&D

Emilce Cano, Bs.

Project Manager

Novel products proposing alternative and innovative therapeutic strategies

Support Laminar Pharma

If you want to get involved in this promising project and join us as an investor, employee, researcher, collaborator, partner, licensee,… feel free to contact us and we will be happy to evaluate a potential mutually beneficial collaboration.